These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 34110536)

  • 1. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders.
    Lasheen NN; Allam S; Elgarawany A; Aswa DW; Mansour R; Farouk Z
    J Physiol Sci; 2024 Sep; 74(1):46. PubMed ID: 39313800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab.
    Shi M; Chu F; Zhu F; Zhu J
    Front Aging Neurosci; 2022; 14():870517. PubMed ID: 35493943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
    Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
    Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive immunotherapy for Alzheimer's disease: challenges & future directions.
    Yi LX; Tan EK; Zhou ZD
    J Transl Med; 2024 May; 22(1):430. PubMed ID: 38715084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive immunotherapy for Alzheimer's disease.
    Guo X; Yan L; Zhang D; Zhao Y
    Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
    Vitek GE; Decourt B; Sabbagh MN
    Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Alzheimer's disease: focusing on the efficacy of gantenerumab on amyloid-β clearance and cognitive decline.
    Azargoonjahromi A
    J Pharm Pharmacol; 2024 Sep; 76(9):1115-1131. PubMed ID: 38767981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
    Fedele E
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Causal treatment of Alzheimer's disease: amyloid antibodies].
    Pawlowski M; Warnecke T
    Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.
    Jin M; Noble JM
    eNeuro; 2024 Sep; 11(9):. PubMed ID: 39332901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.